Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for KalVista Pharmaceuticals (KALV) over the last 10 years, with Q4 2024 value amounting to $46.7 million.

  • KalVista Pharmaceuticals' Shares Outstanding (Weighted Average) rose 3509.02% to $46.7 million in Q4 2024 from the same period last year, while for Oct 2024 it was $46.7 million, marking a year-over-year increase of 3509.02%. This contributed to the annual value of $36.8 million for FY2024, which is N/A changed from last year.
  • KalVista Pharmaceuticals' Shares Outstanding (Weighted Average) amounted to $46.7 million in Q4 2024, which was up 3509.02% from $46.2 million recorded in Q3 2024.
  • KalVista Pharmaceuticals' 5-year Shares Outstanding (Weighted Average) high stood at $46.7 million for Q4 2024, and its period low was $17.7 million during Q2 2020.
  • Its 4-year average for Shares Outstanding (Weighted Average) is $29.3 million, with a median of $34.4 million in 2023.
  • As far as peak fluctuations go, KalVista Pharmaceuticals' Shares Outstanding (Weighted Average) skyrocketed by 47.18% in 2020, and later soared by 3509.02% in 2024.
  • Over the past 4 years, KalVista Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarter) stood at $17.9 million in 2020, then rose by 0.3% to $18.0 million in 2021, then surged by 92.44% to $34.6 million in 2023, then surged by 35.09% to $46.7 million in 2024.
  • Its Shares Outstanding (Weighted Average) was $46.7 million in Q4 2024, compared to $46.2 million in Q3 2024 and $36.8 million in Q2 2024.